Then, at the Georgia Cancer Center at Augusta University, he began the research that would eventually spin off into his first startup, Georgiamune. The same month, Georgiamune also got FDA clearance to begin human clinical trials for its first cancer drug candidate. Georgiamune's primary drug target works to solve a problem posed by another type of cancer drug on the market, called checkpoint inhibitors. For a Series A biotech startup, Georgiamune has an unusually extensive pipeline, with nine biological targets identified internally, all of which use different mechanisms of action than existing drugs. AdvertisementHere's the 21-slide pitch deck Georgiamune used to raise a $75 million Series A co-led by General Catalyst.

---

Persons: —, Samir Khleif, King, Khleif, Catalyst, CJNV BioVenture, Georgiamune, doesn't, Amy Abernethy, Khleif's, General Catalyst Organizations: Service, King Hussein Cancer Center, Georgia Cancer Center, Augusta University, Business, Parker Institute for Cancer, Mubadala, Alexandria Venture Investments, Catalio Capital Management, Verition Fund Management, Bicara Therapeutics, Therapeutics, General Locations: Jordan, Verily